KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Shares Repurchased: 2018-2025

Historic Shares Repurchased for Regeneron Pharmaceuticals (REGN) over the last 7 years, with Sep 2025 value amounting to $664.0 million.

  • Regeneron Pharmaceuticals' Shares Repurchased fell 9.67% to $664.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 94.86%. This contributed to the annual value of $2.6 billion for FY2024, which is 16.48% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Shares Repurchased stood at $664.0 million for Q3 2025, which was down 37.45% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Shares Repurchased ranged from a high of $1.1 billion in Q2 2025 and a low of $166.4 million during Q3 2021.
  • For the 3-year period, Regeneron Pharmaceuticals' Shares Repurchased averaged around $691.4 million, with its median value being $688.8 million (2023).
  • In the last 5 years, Regeneron Pharmaceuticals' Shares Repurchased plummeted by 93.96% in 2021 and then soared by 461.66% in 2022.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Shares Repurchased stood at $866.9 million in 2021, then plummeted by 50.27% to $431.1 million in 2022, then slumped by 32.96% to $289.0 million in 2023, then spiked by 236.68% to $973.0 million in 2024, then dropped by 9.67% to $664.0 million in 2025.
  • Its last three reported values are $664.0 million in Q3 2025, $1.1 billion for Q2 2025, and $1.0 billion during Q1 2025.